Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05440786 · ClinicalTrials.gov registry record · Phase 2
CAMPFIRE: A Study of Abemaciclib (LY2835219) in Participants With Ewing's Sarcoma
A Phase 2 study of Neoplasm Metastasis and Sarcoma, Ewing, sponsored by Eli Lilly and Company.
- Active
- Registry status
- Phase 2
- Development phase
- 46
- Enrollment target
- 20
- Study locations
NCT05440786: Active Phase 2 study of Neoplasm Metastasis and Sarcoma, Ewing, sponsored by Eli Lilly and Company.
NCT05440786 is a Phase 2 study of Neoplasm Metastasis and Sarcoma, Ewing that is active but no longer recruiting, run by Eli Lilly and Company. The registered enrollment target is 46 participants, below the 415-participant average among 41 other Neoplasm Metastasis trials with a reported enrollment target (89% lower). The trial reports 20 study locations across 16 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05440786, a Phase 2 study of Neoplasm Metastasis and Sarcoma, Ewing, is active but no longer recruiting, sponsored by Eli Lilly and Company.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 46 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to measure the benefit of adding abemaciclib to chemotherapy (irinotecan and temozolomide) for Ewing's sarcoma that has come back or did not respond to treatment. This trial is part of the CAMPFIRE master protocol, which is a platform to speed development of new treatments for children and young adults with cancer. Your participation in this trial could last 11 months or longer, depending on how you and your tumor respond.
Primary Outcome
PFS was defined as the time from randomization until the first occurrence of documented disease progression per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) criteria, or death from any cause in absence of progressive disease, whichever came first. Progressive disease (PD) was defined as at least 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 millimeter (mm), or unequivocal
Conditions Studied
Interventions
- DRUG Temozolomide
- DRUG Abemaciclib
- DRUG Irinotecan
Study Locations (20)
Other
- Charité Campus Virchow-Klinikum - Berlin
- IRCCS Istituto Ortopedico Rizzoli - Bologna
- Kyushu University Hospital - Fukuoka
Victoria
- Peter MacCallum Cancer Centre - Melbourne
- Royal Children's Hospital - Melbourne
Barcelona [Barcelona]
- Hospital Universitari Vall d'Hebron - Barcelona
- Hospital Sant Joan de Déu - Esplugues de Llobregat
Arizona
- Phoenix Children's Hospital - Phoenix
California
- The Regents of the University of California - Los Angeles (UCLA Pediatrics) - Los Angeles
Indiana
- Riley Hospital for Children at Indiana University Health - Indianapolis
Missouri
- Washington University - St Louis
Rhode Island
- Lifespan Cancer Institute - Providence
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 2022-09-20 |
| Est. Completion | 2028-09 |
| Phase | Phase 2 |
What the registry record for NCT05440786 still lists
NCT05440786 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 46 participants, a relatively small participant target, below the 415-participant average among 41 other Neoplasm Metastasis trials with a reported enrollment target (89% lower).
The record links to 2 conditions, with Neoplasm Metastasis appearing as the primary indexed condition, and to 3 interventions - of which Temozolomide is the first listed.
NCT05440786 names 20 study sites across 16 states, led by Other, Victoria, Barcelona [Barcelona].
Frequently Asked Questions
What is clinical trial NCT05440786 about?
NCT05440786 is a clinical study titled "CAMPFIRE: A Study of Abemaciclib (LY2835219) in Participants With Ewing's Sarcoma". The purpose of this study is to measure the benefit of adding abemaciclib to chemotherapy (irinotecan and temozolomide) for Ewing's sarcoma that has come back or did not respond to treatment. This trial is part of the CAMPFIRE master protocol, which is a platform to speed development of new treatmen...
What is the current status of trial NCT05440786?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 46 participants. The study started on 2022-09-20. Estimated completion is 2028-09.
What conditions does trial NCT05440786 study?
This clinical trial studies the following conditions: Neoplasm Metastasis, Sarcoma, Ewing.
What interventions are being tested in trial NCT05440786?
The interventions under investigation include: Temozolomide (DRUG), Abemaciclib (DRUG), Irinotecan (DRUG).
Who is sponsoring clinical trial NCT05440786?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05440786 being conducted?
This trial has 20 study locations across Arizona, California, Indiana, Missouri, Rhode Island. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neoplasm Metastasis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05440786's enrollment target sits among peer trials
46 31st of 41 higher than 10 of 41 other Neoplasm Metastasis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Neoplasm Metastasis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
9-ING-41 in Patients with Advanced Cancers
ACTIVE NOT RECRUITING · Phase 2
-
A Safety Extension Study of Trastuzumab Emtansine in Participants Previously Treated With Trastuzumab Emtansine Alone or in Combination With Other Anti-Cancer Therapy in One of the Parent Studies
ACTIVE NOT RECRUITING · Phase 2
-
Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 Genes (PRECISION 1)
ACTIVE NOT RECRUITING · Phase 2
-
Cetuximab Plus Biweekly Capecitabine and Oxaliplatin in KRAS Wild Type Metastatic Colorectal Cancer
COMPLETED · Phase 2
-
Use of Cetuximab for Unresectable or Metastatic Esophageal and Gastric Cancer
COMPLETED · Phase 2
-
Lymphocyte Re-infusion During Immune Suppression to Treat Metastatic Melanoma
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01890590 · 46 participants · NA
A Phase II Study of Cyberknife Radiosurgery for Renal Cell Carcinoma
- NCT03191149 · 46 participants · Phase 2
Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
- NCT03510208 · 46 participants · Phase 1
Panitumumab-IRDye800 in Diagnosing Participants With Malignant Glioma Undergoing Surgery
- NCT04048278 · 46 participants · Early Phase 1
Lidocaine Infusion in Pancreatic Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI